Member Info for EmeraldCarrots

What a dilema!

All IMHO.

As far as the 5% shown it's the same way all shares are reported! Same whether up or down. Seems fair enough to me.

As in investor in AGL obviously I prefer to point out any good news. Again fair enough I would have thought!

I really DO believe Angle have a lot going for them. I don't see how any other conclusion can be reached.

IMHO any deal with say a Molecule analysis firm, firm doing a major trial that opts for the PD-L1 test assay (seems certain to me as the PD-L1 test has cornered the market, has it not? There is no other way...?), positive news on the Bioview contract, major trading upturn generally and many others could easily send the sp North of 20p in my opinion. In fact this is what I am waiting for. Frankly, I expect. I would not be very surprised if the sp leaped to over 20p a share. Really.

One of the things Angle were guilty of IMHO was trying to pursue too many doors the parsortix machine opened. If they had concerntrated more on the most promising ones first and the assays I think the sp would be in far better shape now.

Nevertheless they have a unique machine which can separate cancerous live Circulating Tumour Cells (CCT's) from a standard blood test. They think they are 5 years ahead of the competition. Apart from the uses that have been identified SO FAR from being able to relatively easily "catch" those cells who knows what the future holds?

All IMHO.

Hello.

"Up 5%".

I don't see how anyone can criticise pointing out the sp is up 5% on tand particular day?

What is the problem? Maybe you have a short position??

It is not a lie (as we get here a lot) as you can see the same at the top of the screen.

Maybe I shopuld have posted "Up 25%" instead as posting complete untrue rubbish is ok with some on the board.

What a joke.

LOL!

Al IMHO.

Davyuk.

"Some chunky traders gone through this morning. Someone must see value here, especially after reading the Berenberg assessment giving a target price of 120p."

=============================

Why don't you make up some positive news about Angle Plc?

It does not have to be true as far as some posters here are concerned on here.

See other posts here.

I mean, who cares??

LOL!

All IMHO.

I take it you have no problem when people post things like:-

-----------------

They are doing a money raise.

It's a rights issue.

------------------

Apart from anything else making statements like that could get someone in serious trouble when it's untrue. Really.

I suppose you don't care about that?

-----------------------------------------------------------

I think you will find that my posts are based on facts from the official RNS's and not complete fabrication/lies which you don't seem to have a problem with! Amazing.

All IMHO of course.

Reminds me of around the time of the financial crisis in 2008 when someone working for a big investment house got it wrong and ACCIDENTLY bought a controlling interest in a small USA Plc!!! The trade was subsequently reversed. LOL!

Can someone explain how this appeared?

How can a trade like this happen when the bid was £1.626 and the ask £1.627. Plus the sp has been no-where near £1.86 all year. Only just above £1.70???????????????????

Up 5%. Possiby why........

They have worldwide patents on their parsortix machine.

A machine that can separate out a single circulating cancer cell (cct) from a standard blood sample.

This enables a cancer that has matastacised (spread) to be analysed/tested from a simple standard blood test. The results give UP TO DATE valuable information about a persons cancer. Often a matastacised cancer cannot be analysed/tested because the original tumour was cut out months/years earlier and a cancer CHANGES OVER TIME. This makes the results of the original test UNRELIABLE and could result in the WRONG TREATMENT being selected.

****The issue has been how to monetize this technology****.

It's been 7 months since Angle announced the contract with Bioview to develop the HER2 assay and that as far as I can see could be a massive money spinner. This gives me confidence as obviously the Directors of Bioview Ltd would not invest £1.2 million of their money unless they expect a very good return would they? The HER2 status of breast cancer is a prime example of how the parsortix machine can help select the appropriate treatment. The HER2 status of breast cancer can change over time. A different status (positive or negative) is important in treatment selection. If the HER2 status of a persons cancer has changed since the original biopsy the WRONG treatment might be selected. Being able to do an UP TO DATE test is clearly vital to ensure the correct treatment is selected.

The PD-L1 assay, announced just the other day is now available. I think this is another potential big money spinner.

PD-L1 is an immune-related biomarker that can be on the surface of tumour cells across a range of cancer types, and this biomarker enables cancer cells to evade a persons immune response mechanisms. Some immunotherapy Companies use PD-1/PD-L1 inhibitors to stop the cancer cells from beng able to evade a persons immune response which would otherwise kill the cancer cell.

The Companies that sell these therapies have a big problem in that they are often unable to test the PD-L1 status of a patient just before and during treatment. Once again the reason being these cancers can change over time and the original biopsy may have been done months or years before and cannot be done again. They need to have this ability during their immunotherapy trials to gather valuable data. From a test just before treatment they would be able to find out the levels of PD-1/PD-L1 in cancers that responded best. Then during treatment monitor these levels to get an early indication whether the treatment is working. Finally this data could be used to target people best suited to the treatment and in time Angle's assay could be used for patient selection, a potentially massive market.

A sample of what lies ahead I believe.

All IMHO. Do your own research..

Is this why?

They have worldwide patents on their parsortix machine.

A machine that can separate out a single circulating cancer cell (cct) from a standard blood sample.

This enables a cancer that has matastacised (spread) to be analysed/tested from a simple standard blood test. The results give UP TO DATE valuable information about a persons cancer. Often a matastacised cancer cannot be analysed/tested because the original tumour was cut out months/years earlier and a cancer CHANGES OVER TIME. This makes the results of the original test UNRELIABLE and could result in the WRONG TREATMENT being selected.

****The issue has been how to monetize this technology****.

It's been 7 months since Angle announced the contract with Bioview to develop the HER2 assay and that as far as I can see could be a massive money spinner. This gives me confidence as obviously the Directors of Bioview Ltd would not invest £1.2 million of their money unless they expect a very good return would they? The HER2 status of breast cancer is a prime example of how the parsortix machine can help select the appropriate treatment. The HER2 status of breast cancer can change over time. A different status (positive or negative) is important in treatment selection. If the HER2 status of a persons cancer has changed since the original biopsy the WRONG treatment might be selected. Being able to do an UP TO DATE test is clearly vital to ensure the correct treatment is selected.

The PD-L1 assay, announced just the other day is now available. I think this is another potential big money spinner.

PD-L1 is an immune-related biomarker that can be on the surface of tumour cells across a range of cancer types, and this biomarker enables cancer cells to evade a persons immune response mechanisms. Some immunotherapy Companies use PD-1/PD-L1 inhibitors to stop the cancer cells from beng able to evade a persons immune response which would otherwise kill the cancer cell.

The Companies that sell these therapies have a big problem in that they are often unable to test the PD-L1 status of a patient just before and during treatment. Once again the reason being these cancers can change over time and the original biopsy may have been done months or years before and cannot be done again. They need to have this ability during their immunotherapy trials to gather valuable data. From a test just before treatment they would be able to find out the levels of PD-1/PD-L1 in cancers that responded best. Then during treatment monitor these levels to get an early indication whether the treatment is working. Finally this data could be used to target people best suited to the treatment and in time Angle's assay could be used for patient selection, a potentially massive market.

A sample of what lies ahead I believe.

All IMHO. Do your own research.

Hello.

Brent crude down to $78.43.

3 weeks ago it was North of $85.

4 weeks ago it was North of $90....................

Ftse up 0.75%

Don't care about bonds, just shares!

Nice.

The lower the better.

Excellent!!!

Great!!

Good.

Pokerchips.

I take it snappers posts are suspect? I have copied them in case LSE remove them.

Wondering if I should send them to PFC to see what they think?

Snapper10.

You say you "resigned from the LT Project".

I am simply asking what project it was? Don't you know!